Pohl O

No ORCID on file · 3 papers in corpus · active 2014-2021

Study types

  • article 3

Condition tags

  • dysmenorrhea 1
  • endometriosis 1
  • chronic_pelvic_pain 1
article 2021
A model‐based analysis to guide gonadotropin‐releasing hormone receptor antagonist use for management of endometriosis
British journal of clinical pharmacology ·doi:10.1111/bcp.15171

AIMS: To identify linzagolix doses, an oral GnRH receptor antagonist, that effectively lower oestradiol (E2) to relieve endometriosis-related pelvic pain without compromising bone health. METHODS: Integrated statistical, pharmacokinetic-pha…

article 2020
Effects of combined GnRH receptor antagonist linzagolix and hormonal add-back therapy on vaginal bleeding—delayed add-back onset does not improve bleeding pattern
Reproductive sciences (Thousand Oaks, Calif.) ·doi:10.1007/s43032-020-00172-z

Linzagolix is a novel, oral GnRH receptor antagonist developed for the treatment of endometriosis and uterine fibroids. We assessed high-dose linzagolix safety and bleeding pattern effects in healthy women using combined versus delayed horm…

article 2014
Synergistic Effects of E2MATE and Norethindrone Acetate on Steroid Sulfatase Inhibition: A Randomized Phase I Proof-of-Principle Clinical Study in Women of Reproductive Age
Reproductive sciences (Thousand Oaks, Calif.) ·doi:10.1177/1933719114522526

The combination of a progestin such as norethindrone acetate (NETA) reducing the ovarian estrogen production with a steroid sulfatase (STS) inhibitor (STS-I) decreasing the local estrogen production could result in a new treatment option fo…